Moleculin Biotech receives Nasdaq delisting notice for failing minimum stockholders' equity rule

Moleculin Biotech, Inc.

Nasdaq notified Moleculin on May 23, 2025, that it does not meet Listing Rule 5550(b)(1) requiring $2.5M in stockholders' equity.
The company has 45 calendar days to submit a plan to regain compliance; if accepted, a 180-day extension may be granted.
Failure to regain compliance could lead to delisting from the Nasdaq Capital Market; no immediate effect on trading.
The company may appeal any adverse Staff determination to the Nasdaq Hearings Panel.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.